NEW YORK — PathSensors said on Thursday that it has signed an agreement expanding its exclusive license to a Massachusetts Institute of Technology-developed pathogen detection technology to include clinical applications.
According to the Baltimore-based company, its first clinical application of the technology will be for SARS-CoV-2.